A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Eligible age
18–70 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Sponsor: Verve Therapeutics, Inc.
You may qualify if…
- ✓ Diagnosis of HeFH or premature CAD
You may not qualify if…
- ✕ Homozygous familial hypercholesterolemia
- ✕ Active or history of chronic liver disease
- ✕ Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- ✕ Clinically significant or abnormal laboratory values as defined by the protocol
Where it's recruiting
Dothan
Pomona
Boca Raton · Jacksonville · Winter Park
High Point
DeSoto
Renton
Source: ClinicalTrials.gov · NCT06164730 · last updated 2026-06-02